The Beacon Aqueous Microshunt is an investigational medical device implanted in the eye to treat glaucoma.
The Beacon Aqueous Microshunt (BAM) is available to patients enrolled in a clinical study. You (or someone you know) may qualify for a clinical study evaluating the BAM if you have glaucoma and continue to have elevated eye pressure despite use of medication, prior glaucoma surgery, or both.
Clinical studies are currently enrolling patients between the ages of 22-85 years with primary open angle glaucoma, traumatic glaucoma and neovascular glaucoma in the United States, Canada, Germany and Austria. If interested in participating in a clinical trial of Beacon, discuss the risks – and potential benefits – with a participating investigator.
Improve Your Outlook
Investigational medical devices are available to patients enrolled in a clinical study. Refractory glaucoma is a term used to describe glaucoma where prior treatments, such as surgery, medication or both, have failed to control pressure in the eye.
Clinical studies are underway to evaluate the safety and effectiveness of Beacon.
If you are interested making medical history with us by participating in one of our clinical trials, check out the clinical studies below.